Document is current
Any future updates will be listed below
-
Authors
Sagard, Jonas http://orcid.org/0000-0001-7227-0665
Olofsson, Tor
Mogard, Elisabeth
Marsal, Jan
Andréasson, Kristofer
Geijer, Mats
Kristensen, Lars Erik
Lindqvist, Elisabet
Wallman, Johan K.
-
Funding
Funding for this research was provided by:
Skånes universitetssjukhus
Reumatikerförbundet
Anna-Greta Crafoords stiftelse
Kock Foundation
Alfred Österlunds Stiftelse
Stiftelsen Professor Nanna Svartz Fond
Lundgren Foundation
Hedlund Foundation
Grants from the Swedish government to researchers in public health care
Lund University
- License Information
-
More Information
Article History
Received: 23 September 2021
Accepted: 31 January 2022
First Online: 12 February 2022
Declarations
:
: Ethical approval for the SPARTAKUS study was granted by the Regional Ethics Committee in Lund, Sweden (Dnr. 2015/436 with amendment Dnr. 2018/238). Oral and written informed consent was acquired from all patients and controls before entry into the study, which was performed in accordance with the Helsinki Declaration.
: Not applicable.
: JS: None declared. TO: Consultant of Eli Lilly, Merck Sharp & Dohme. EM: Consultant of Novartis. JM: Speakers bureau of AbbVie, Bristol-Myers Squibb, Ferring, Janssen Pharmaceuticals, Pfizer, Takeda, Tillotts; Consultant of AbbVie, Janssen Pharmaceuticals, Pfizer, Takeda; Grant/research support from AbbVie, Ferring, Pfizer, Takeda. KA: None declared. MG: Speakers bureau of AbbVie, Novartis, Pfizer, UCB Pharma. LEK: Speakers bureau of AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen Pharmaceuticals, Merck Sharp & Dohme, Novartis, Pfizer, UCB Pharma; Consultant of AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen Pharmaceuticals, Merck Sharp & Dohme, Novartis, Pfizer, UCB Pharma; EL: None declared. JKW: Consultant of AbbVie, Amgen, Celgene, Eli Lilly, Novartis.
